← Leaderboards
Vinay Aakalu
Jesse Brown Va Medical Center
$5,380,811
Attributed
$6,548,584
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,548,584 · 6
VA$0 · 1
By mechanism
R01$4,272,294 · 2
K08$1,182,135 · 1
P30$1,094,155 · 3
I01$0 · 1
Top collaborators
- Stephanie M Cologna5 shared
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectFunctional DisorderProteinsPeptidesCell Culture TechniquesQuality Of LifeProductionFilmNovel TherapeuticsLacrimalHistatin 1Ocular SurfacePropertyCellsIn VitroMouse ModelIn VivoHistidine-Rich ProteinsEye DrynessExperimental StudyEye DiseasesDesignAntimicrobialDisease Model
Grant awards (26)
Novel Therapeutic Approaches for NPC Disease$575,579
R01 · FY2025 · NS
Cellular and Molecular Biology Core$183,746
P30 · FY2025 · EY · contact PI
Novel Therapeutic Approaches for NPC Disease$558,314
R01 · FY2024 · NS
Cellular and Molecular Biology Core$183,746
P30 · FY2024 · EY · contact PI
Novel Therapeutic Approaches for NPC Disease$43,899
R01 · FY2024 · NS
Novel Therapeutic Approaches for NPC Disease$575,579
R01 · FY2023 · NS
Novel Treatments for Ocular Surface Diseases$388,089
R01 · FY2023 · EY · contact PI
Cellular and Molecular Biology Core$183,746
P30 · FY2023 · EY · contact PI
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases$0
I01 · FY2023 · VA · contact PI
Novel Therapeutic Approaches for NPC Disease$582,175
R01 · FY2022 · NS
Novel Treatments for Ocular Surface Diseases$387,758
R01 · FY2022 · EY · contact PI
Cellular and Molecular Biology Core$183,746
P30 · FY2022 · EY · contact PI
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases$0
I01 · FY2022 · VA · contact PI
Novel Treatments for Ocular Surface Diseases$387,757
R01 · FY2021 · EY · contact PI
Cellular and Molecular Biology Core$183,746
P30 · FY2021 · EY · contact PI
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases$0
I01 · FY2021 · VA · contact PI
Novel Treatments for Ocular Surface Diseases$399,750
R01 · FY2020 · EY · contact PI
Cellular and Molecular Biology Core$175,425
P30 · FY2020 · EY · contact PI
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases$0
I01 · FY2020 · VA · contact PI
Novel Treatments for Ocular Surface Diseases$373,394
R01 · FY2019 · EY · contact PI
Novel Treatments for Modulation of Innate Immunity in Veteran Related Eye Diseases$0
I01 · FY2019 · VA · contact PI
Study of Accessory Lacrimal Gland and Precursor Cell Biology$236,427
K08 · FY2018 · EY · contact PI
Study of Accessory Lacrimal Gland and Precursor Cell Biology$236,427
K08 · FY2017 · EY · contact PI
Study of Accessory Lacrimal Gland and Precursor Cell Biology$236,427
K08 · FY2016 · EY · contact PI
Study of Accessory Lacrimal Gland and Precursor Cell Biology$236,427
K08 · FY2015 · EY · contact PI
Study of Accessory Lacrimal Gland and Precursor Cell Biology$236,427
K08 · FY2014 · EY · contact PI